- Home
- PWP vs IMTX Comparison
PWP vs IMTX Comparison
Compare PWP & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PWP | IMTX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PWP | IMTX |
|---|---|---|
| Price | $16.61 | $8.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $23.50 | $19.00 |
| AVG Volume (30 Days) | ★ 1.2M | 475.1K |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ 138.52 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.86 | N/A |
| Revenue Next Year | $18.95 | $25.91 |
| P/E Ratio | $199.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.11 | $5.05 |
| 52 Week High | $25.93 | $12.41 |
Technical Indicators
Market Signals| Indicator | PWP | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 43.91 |
| Support Level | $14.53 | $8.60 |
| Resistance Level | $17.15 | $10.41 |
| Average True Range (ATR) | 0.74 | 0.42 |
| MACD | -0.12 | -0.05 |
| Stochastic Oscillator | 30.90 | 33.54 |
Price Performance
Historical ComparisonAbout PWP Perella Weinberg Partners
Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.